JAMA Network
About The Study: This cross-sectional study found that glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and misuse were common in a targeted sample of people with eating disorders. The prevalence of lifetime GLP-1 RA use was higher among people with eating disorders than the 15% observed in the general adult population. People with eating disorders are a clinically diverse population who may be consuming GLP-1 RAs in contraindicated ways to maintain eating disorder psychopathology through rapid restriction and weight loss.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
